Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

A Multicenter Prospective Clinical Study of Venetoclax Combined with Azactidine in the Treatment of Newly Diagnosed Acute Leukaemias of Ambiguous Lineage: Interim Analysis of a Phase 2 Trial

Si-Man Huang, Tong-Tong Zhang, Lan Dai, Chao-Ling Wan, Han-Yu Cao, Hai-Ping Dai, Ming-Zhu Xu, Depei Wu, Sheng-Li Xue

Blood (2024) 144 (Supplement 1): 5899.

https://doi.org/10.1182/blood-2024-204660

Published: 2024

Journal Articles

Should Transplant Centers Prioritize Further Stem Cell Collection for Future CAR T-Cell Therapy Boosts? an Economic and Clinical Assessment

Ehsan Malek, Marco Davila, Hector Tirado, Shernan G. Holtan, Brian Betts, Han Yu

Blood (2024) 144 (Supplement 1): 7252.

https://doi.org/10.1182/blood-2024-200893

Published: 2024

Journal Articles

Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification

Chao-Ling Wan, Yu-Qing Liu, Fang-Tong Liu, Yuan-Hong Huang, Han-Yu Cao, Si-Man Huang, Kai-Wen Tan, Zihao Wang, Shuai-Shuai Ge, Miao Wang, Haiping Dai, Sheng-Li Xue

Blood (2024) 144 (Supplement 1): 1527.

https://doi.org/10.1182/blood-2024-197933

Published: 2024

Journal Articles

Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study

Fangtong Liu, Chao-Ling Wan, Yu-Qing Liu, Yuan-Hong Huang, Han-Yu Cao, Si-Man Huang, Kai-Wen Tan, Shuai-Shuai Ge, Miao Wang, Mei-Jing Liu, Zihao Wang, Sheng-Li Xue, Haiping Dai

Blood (2024) 144 (Supplement 1): 1484.

https://doi.org/10.1182/blood-2024-202500

Published: 2024

Journal Articles

Impact of Social Determinants of Health on Survival Outcomes in Multiple Myeloma Patients at a Major Cancer Center

Esraa Abdalla, Malak Alharbi, Sawyer Bawek, Catherine Forbes, Ian Lund, Han Yu, Berthliz Durand, Jens Hillengass, Hamza Hassan, Eugene Przespolewski

Blood (2024) 144 (Supplement 1): 5158.

https://doi.org/10.1182/blood-2024-206022

Published: 2024

Journal Articles

Venetoclax Combined with Azacitidine Was Effective and Safe for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma: Preliminary Results of a Phase 2, Multicenter Trial

Han-Yu Cao, Lu-Lu Chen, Chao-Ling Wan, Xiao-Hui Hu, Bing Wu, Li Yang, Li Wang, Yang Zhang, De-Pei Wu, Hai-Ping Dai, Hao Zhang, Shengli Xue

Blood (2023) 142 (Supplement 1): 1501.

https://doi.org/10.1182/blood-2023-179733

Published: 2023

Journal Articles

Inotuzumab Ozogamicin + Blinatumumab +/- Rituximab + Mini-Hcvd Shows Improved Tolerability with Similar Efficacy Compared to E1910 in Treatment of Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia in Older Adults

Jordan Scott, Samantha Poblete, Jared Vega, Amanda C. Przespolewski, James E Thompson, Elizabeth A. Griffiths, Pamela Jeannette Sung, Steven Green, Han Yu, Michael Shenal, Eugene Przespolewski, Eunice S. Wang, Jeffrey Baron

Blood (2023) 142 (Supplement 1): 5891.

https://doi.org/10.1182/blood-2023-181332

Published: 2023

Journal Articles

RUNX1 Mutation Does Not Significantly Impact the Outcome of Newly Diagnosedadult AML: A Retrospective Study of Chinese AML Patients

Chao-Ling Wan, Yuan-Hong Huang, Si-Man Huang, Tong-Tong Zhang, Kai-Wen Tan, Yan Qiu, Xiang-Dong Shen, Shuai-Shuai Ge, Han-Yu Cao, Yan-Yan Li, Songbai Liu, Qiao-Cheng Qiu, Haiping Dai, Sheng-Li Xue

Blood (2023) 142 (Supplement 1): 4216.

https://doi.org/10.1182/blood-2023-185390

Published: 2023

Journal Articles

MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis

Mark G. Faber, Jeffrey Baron, Han Yu, Hassan Awada, Tara L. Cronin, James E. Thompson, Amanda Przespolewski, Steven D. Green, Pamela J. Sung, Elizabeth A. Griffiths, Eunice S. Wang

Blood (2022) 140 (Supplement 1): 9010–9012.

https://doi.org/10.1182/blood-2022-164707

Published: 2022

Journal Articles

Retrospective Comparison of the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) 21-Day Schedule Vs. 28-Day Schedule in Patients with Newly Diagnosed Multiple Myeloma

Alina Varabyeva, Jens Hillengass, Wenyan Ji, Han Yu, McKenna Butler, Eugene Przespolewski

Blood (2021) 138 (Supplement 1): 1643.

https://doi.org/10.1182/blood-2021-151182

Published: 2021

Journal Articles

ASXL1 Mutation Is a Novel Risk Factor for Bleeding in Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN)

Amro Elshoury, Han Yu, Wenyan Ji, James E. Thompson, Elizabeth A. Griffiths, Amanda Przespolewski, Steven Daniel Green, Pamela J. Sung, Sheeba baAqeel, Hassan Awada, Eunice S. Wang, Peter A. Kouides

Blood (2021) 138 (Supplement 1): 3637.

https://doi.org/10.1182/blood-2021-146384

Published: 2021

Journal Articles

Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials

Smith Giri, MBBS, Madan R Aryal, MD, Han Yu, PhD, Alyssa Grimshaw, MSLIS, Ranjan Pathak, MD, Scott F. Huntington, MD MPH, Binod Dhakal, MBBS

Blood (2019) 134 (Supplement_1): 2188.

https://doi.org/10.1182/blood-2019-130389

Published: 2019

Journal Articles

Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study

Jeffrey Baron, PharmD, Christina L. Lombardi, PharmD, Han Yu, PhD, Amanda Przespolewski, DO, Elizabeth A. Griffiths, MD, James E. Thompson, MD, Swapna Thota, MD, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 3501.

https://doi.org/10.1182/blood-2019-131629

Published: 2019

Journal Articles

Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression

Han-Yu Chuang, Laura Rassenti, Michelle Salcedo, Kate Licon, Alexander Kohlmann, Torsten Haferlach, Robin Foà, Trey Ideker, Thomas J. Kipps

Blood (2012) 120 (13): 2639–2649.

https://doi.org/10.1182/blood-2012-03-416461

Published: 2012

Includes: Supplemental data

Journal Articles

Subnetwork-Based Analysis of Chronic Lymphocytic Leukemia Identifies Pathways That Associate with Disease Progression,

Han-Yu Chuang, Laura Z. Rassenti, Ph.D., Michelle Salcedo, BS, Kate Licon, Alexander Kohlmann, PhD, Torsten Haferlach, MD, Robin Foa, Trey Ideker, PhD, Thomas Kipps

Blood (2011) 118 (21): 3564.

https://doi.org/10.1182/blood.V118.21.3564.3564

Published: 2011

Journal Articles

B Cell Activating Factor and c-Myc Regulate the Progression of Chronic Lymphocytic Leukemia.

Weizhou Zhang, PhD, Arnon P. Kater, MD, PhD, Han-Yu Chuang, Thomas Enzler, MD, PhD, George F. Widhopf, II, PhD, Danelle James, MD, Harvey Herschman, Michael Karin, PhD, Thomas J. Kipps, MD, PhD

Blood (2009) 114 (22): 359.

https://doi.org/10.1182/blood.V114.22.359.359

Published: 2009

Journal Articles

Chronic lymphocytic leukemia of Eμ- TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression

Thomas Enzler, Arnon P. Kater, Weizhou Zhang, George F. Widhopf, II, Han-Yu Chuang, Jason Lee, Esther Avery, Carlo M. Croce, Michael Karin, Thomas J. Kipps

Blood (2009) 114 (20): 4469–4476.

https://doi.org/10.1182/blood-2009-06-230169

Published: 2009

Includes: Supplemental data

Journal Articles

Interactome-Based Molecular Prognosis of Chronic Lymphocytic Leukemia

Han-Yu Chuang, Laura Rassenti, PhD, Trey Ideker, PhD, Thomas J. Kipps, MD, PhD

Blood (2008) 112 (11): 545.

https://doi.org/10.1182/blood.V112.11.545.545

Published: 2008

Journal Articles

Expression of Lymphocyte Activation Gene 3 (LAG-3/CD223) by Chronic Lymphocytic Leukemia B Cells.

Han-Yu Chuang, MS, Yu-Tsueng Liu, PhD, Laura Z. Rassenti, PhD, Lang Huynh, BS, Dennis Carson, MD, Thomas J. Kipps, MD, PhD

Blood (2005) 106 (11): 2952.

https://doi.org/10.1182/blood.V106.11.2952.2952

Published: 2005

Journal Articles

Differential Expression Profile of the Proteome and Transcriptome in Aggressive and Indolent Chronic Lymphocytic Leukemia.

Yu-Tsueng Liu, PhD, Laura Z. Rassenti, PhD, Zhouxin Shen, PhD, Han-Yu Chuang, MS, Steven P. Briggs, PhD, Thomas J. Kipps, MD, PhD, Dennis Carson, MD

Blood (2005) 106 (11): 2101.

https://doi.org/10.1182/blood.V106.11.2101.2101

Published: 2005

NARROW

A Multicenter Prospective Clinical Study of Venetoclax Combined with Azactidine in the Treatment of Newly Diagnosed Acute Leukaemias of Ambiguous Lineage: Interim Analysis of a Phase 2 Trial

Should Transplant Centers Prioritize Further Stem Cell Collection for Future CAR T-Cell Therapy Boosts? an Economic and Clinical Assessment

Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification

Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study

Impact of Social Determinants of Health on Survival Outcomes in Multiple Myeloma Patients at a Major Cancer Center

Venetoclax Combined with Azacitidine Was Effective and Safe for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma: Preliminary Results of a Phase 2, Multicenter Trial

Inotuzumab Ozogamicin + Blinatumumab +/- Rituximab + Mini-Hcvd Shows Improved Tolerability with Similar Efficacy Compared to E1910 in Treatment of Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia in Older Adults

RUNX1 Mutation Does Not Significantly Impact the Outcome of Newly Diagnosedadult AML: A Retrospective Study of Chinese AML Patients

MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis

Retrospective Comparison of the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) 21-Day Schedule Vs. 28-Day Schedule in Patients with Newly Diagnosed Multiple Myeloma

ASXL1 Mutation Is a Novel Risk Factor for Bleeding in Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN)

Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials

Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study

Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression

Subnetwork-Based Analysis of Chronic Lymphocytic Leukemia Identifies Pathways That Associate with Disease Progression,

B Cell Activating Factor and c-Myc Regulate the Progression of Chronic Lymphocytic Leukemia.

Chronic lymphocytic leukemia of Eμ- TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression

Interactome-Based Molecular Prognosis of Chronic Lymphocytic Leukemia

Expression of Lymphocyte Activation Gene 3 (LAG-3/CD223) by Chronic Lymphocytic Leukemia B Cells.

Differential Expression Profile of the Proteome and Transcriptome in Aggressive and Indolent Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only